SCHEMBL2014323

SCHEMBL2014323

CCNc1cc(C(=O)OC)ccc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LNPEP Q9UIQ6 6/20 0.56
ERAP2 Q6P179 3/20 0.56
HDAC1 Q13547 1/20 0.55
KDM4E B2RXH2 7/20 0.54
MAPT P10636 7/20 0.54
ALDH1A1 P00352 6/20 0.54
GAA P10253 4/20 0.54
HPGD P15428 3/20 0.54
HSD17B10 Q99714 3/20 0.54
GLA P06280 1/20 0.54
CASP1 P29466 1/20 0.54
CASP7 P55210 1/20 0.54
ATM Q13315 1/20 0.54
THRB P10828 1/20 0.54
HTT P42858 1/20 0.54
GFER P55789 1/20 0.54
PLEC Q15149 1/20 0.54
PTGER4 P35408 1/20 0.47
KMT2A Q03164 1/20 0.47
USP2 O75604 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13497806 0.88 PTGER4 (0.58) LNPEPERAP2KDM4EMAPTALDH1A1
SCHEMBL1205232 0.88 LNPEP (0.57) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL1543144 0.87 GAA (0.71) LNPEPERAP2KDM4EMAPTALDH1A1
SCHEMBL24265280 0.86 HDAC1 (0.53) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL763198 0.85 LNPEP (0.62) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL3063269 0.83 KDM4E (0.57) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL28353995 0.83 LNPEP (0.53) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL20266373 0.83 PTGER4 (0.64) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL29924966 0.83 LNPEP (0.53) LNPEPERAP2HDAC1KDM4EMAPT
SCHEMBL22097615 0.82 KDM4E (0.66) KDM4EMAPTALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304590-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS Enterprise Therapeutics Limited (GB) 2025-10-02 US disclosed
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors Enterprise Therapeutics Limited (GB) 2025-07-29 US disclosed
US-12037336-B2 Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) Enterprise Therapeutics Limited (GB) 2024-07-16 US disclosed
US-20240067653-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS Enterprise Therapeutics Limited (GB) 2024-02-29 US disclosed
US-11739094-B2 Substituted benzodiazoliums as ENaC inhibitors Enterprise Therapeutics Limited (GB) 2023-08-29 US disclosed
EP-3794002-B1 COMPOUNDS ENTERPRISE THERAPEUTICS LTD (GB) 2023-08-02 EP disclosed
WO-2023049518-A1 BENZIMIDAZOLE CARBOXYLIC ACIDS AS GLP-1R AGONISTS TERNS PHARMACEUTICALS, INC. (US) 2023-03-30 WO disclosed
US-11370778-B2 Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases Enterprise Therapeutics Limited (GB) 2022-06-28 US disclosed
CN-110214141-B Benzodiazolium compounds as ENaC inhibitors 企业治疗学有限公司 2022-05-31 CN disclosed
EP-3697788-B1 BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES ENTERPRISE THERAPEUTICS LTD (GB) 2021-12-15 EP disclosed
US-20200239442-A1 BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES Enterprise Therapeutics Limited (GB) 2020-07-30 US disclosed
US-20190315757-A1 BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS Enterprise Therapeutics Limited (GB) 2019-10-17 US disclosed
EP-3544981-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS Enterprise Therapeutics Limited (GB) 2019-10-02 EP disclosed
US-20190233402-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-08-01 US disclosed
WO-2019077340-A1 BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES Enterprise Therapeutics Limited (GB) 2019-04-25 WO disclosed
EP-3472154-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2019-04-24 EP disclosed
WO-2018096325-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS Enterprise Therapeutics Limited (GB) 2018-05-31 WO disclosed
WO-2017221008-A1 COMPOUNDS Enterprise Therapeutics Limited (GB) 2017-12-28 WO disclosed
WO-2011079087-A1 ENAC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-06-30 WO disclosed
WO-2011079087-A1 ENAC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11739094-B2 Substituted benzodiazoliums as ENaC inhibitors NHERF1, SCNN1B, SCNN1A LNPEP 4685/4885ERAP2 3264/4885HDAC1 241/4885
US-20190315757-A1 BENZODIAZOLIUM COMPOUNDS AS ENaC INHIBITORS NHERF1, SCNN1B, SCNN1A LNPEP 4762/4885ERAP2 3038/4885HDAC1 241/4885
US-12371436-B2 Substituted benzodiazoliums as ENaC inhibitors NHERF1, SCNN1B, SCNN1A LNPEP 4685/4885ERAP2 3264/4885HDAC1 241/4885
US-12037336-B2 Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) SCNN1B, SCNN1A, SCNN1G LNPEP 3888/4885ERAP2 1731/4885HDAC1 356/4885
US-20240067653-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS NHERF1, SCNN1B, SCNN1A LNPEP 4762/4885ERAP2 3038/4885HDAC1 241/4885
US-20190233402-A1 COMPOUNDS CFTR, NHERF1, SCNN1A LNPEP 3476/4885ERAP2 1581/4885HDAC1 1090/4885
US-11370778-B2 Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases CFTR, SCNN1B, TRPV3 LNPEP 2570/4885ERAP2 1585/4885HDAC1 1843/4885
US-20200239442-A1 BIS(PENTAHYDROXYHEXYL)AMINO SUBSTITUTED 2-{[(3-AMINO-PYRAZIN-2-YL)FORMAMIDO]METHYL}-1H-1,3-BENZODIAZOL-3-IUM DERIVATIVES AS ENAC INHIBITORS FOR TREATING RESPIRATORY DISEASES CFTR, SCNN1B, TRPV3 LNPEP 2570/4885ERAP2 1585/4885HDAC1 1843/4885
US-20250304590-A1 BENZODIAZOLIUM COMPOUNDS AS ENAC INHIBITORS NHERF1, SCNN1B, SCNN1A LNPEP 4762/4885ERAP2 3038/4885HDAC1 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.